Abbott’s Partner Ends Trial of Kidney Failure Drug

Abbott Laboratories and its development partner ended a trial of one of their top drug candidates, citing complications and death. Abbott fell as analysts said the setback was a blow to the company’s growth prospects.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.